GLP1R

Synonyms

GLP1R, Glucagon-like peptide 1 receptor, Glucagon Like Peptide 1 Receptor, GLP-1 Receptor, GLP-1-R, Seven Transmembrane Helix Receptor, GLP1 Receptor, GLP-1, GLP-1R, Glucagon-Like Peptide-1 Receptor,

Description

Glucagon-like peptide 1 receptor is a receptor protein found on beta cells of the pancreas and on neurons of the brain. It is involved in the control of blood sugar level by enhancing insulin secretion.In humans it is synthesised by the gene GLP1R, which is present on chromosome 6.It is a member of the glucagon receptor family of G protein-coupled receptors.GLP1R is composed of two domains, one extracellular (ECD) that binds the C-terminal helix of GLP-1,and one transmembrane (TMD) domain that binds the N-terminal region of GLP-1.In the TMD domain there is a fulcrum of polar residues that regulates the biased signaling of the receptor while the transmembrane helical boundaries and extracellular surface are a trigger for biased agonism.

KO Status

F1 (+/-)

Drug Information

Launched drugs: 12
Drugs in clinical trials: 60
Latest Research Phase:Approved

Drug Name

Code

Phase

Company

Indications

Clinical Trials

Insulin degludec/Liraglutide

NN-9068

Approved

Novo Nordisk A/S

Diabetes Mellitus, Type 2, Diabetes Mellitus

Semaglutide oral (Novo Nordisk)

OG-217SC, GLP-1-SNAC, NNC0113-0217, NN-9924

Approved

Novo Nordisk A/S

Diabetes Mellitus, Type 2, Diabetes Mellitus

Liraglutide (Jiangsu Chia Tai-Tianqing)

Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Shanghai Institute Of Pharmaceutical Industry, Lianyungang Runzhong Pharmaceutical Co Ltd

Beinaglutide

Approved

Second Military Medical University

Diabetes Mellitus, Type 2, Overweight

Exenatide

Ex-4, AC-2993, LY-2148568, AC-2993-LAR

Approved

Astrazeneca Plc, Eli Lilly And Company

Diabetes Mellitus, Type 2, Renal Insufficiency, Obesity, Diabetes Mellitus

Semaglutide

NN-9535, NNC-0113-0217, NN-9931, NN-9536, 9931

Approved

Novo Nordisk A/S

Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Kidney Diseases, Liver Diseases, Obesity, Renal Insufficiency, Chronic, Diabetes Mellitus, Overweight

Liraglutide

NN-2211, NN-8022, NN-9211, NNC-901170, NNC-90-1170

Approved

Novo Nordisk A/S

Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity, Diabetes Mellitus, Overweight

Lixisenatide

ZP-10, AVE0100, AVE-0010, AQVE-10010

Approved

Zealand Pharma, Sanofi

Diabetes Mellitus, Type 2, Acute Coronary Syndrome, Diabetes Mellitus

Liraglutide (Eastern Virginia Medical School)

Eastern Virginia Medical School

PEG-Loxenatide

PEX-168

Approved

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Diabetes Mellitus, Type 2

Insulin glargine/Lixisenatide

HOE-901/AVE-0010

Approved

Sanofi

Diabetes Mellitus, Type 2

Albiglutide

PGC-GLP-1, GSK-716155

Approved

Glaxosmithkline Plc

Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Heart Failure

Dulaglutide

GLP-1-Fc, LY-2189265

Approved

Eli Lilly And Company

Diabetes Mellitus, Type 2, Cardiovascular Diseases

Exendin-4 (Dongguan Baolijian Bioengineer)

Phase 3 Clinical

Dongguan Baolijian Bioengineering Research And Development Co Ltd

Diabetes Mellitus, Type 2

PEGylated Exenatide

PB-119

Phase 3 Clinical

Paige Biomedicine (Suzhou) Co Ltd, Shanghai Jiaotong University

Diabetes Mellitus, Type 2

Liraglutide (Tonghua Dongbao)

Phase 3 Clinical

Tonghua Dongbao Pharmaceutical Co Ltd, Tonghua Tongbo Biomedicine Co Ltd

Diabetes Mellitus, Type 2

Albenatide

PCDAC, CJC-1134, CJC1134-PC, CJC-1134-PC

Phase 3 Clinical

Hebei Changshan Biochemical Pharmaceutical Co Ltd, Changshan Kaijiejian Biopharmaceutical Development (Hebei) Co Ltd, Conjuchem

Diabetes Mellitus, Type 2

Recombinant exendin 4 (Uni-Bio Science Group)

Uni-E4, Uni rE4, Uni-E4-Fc

Phase 3 Clinical

Uni-Bio Science Group

Diabetes Mellitus, Type 2

rExenatide-4 (Shijiazhuang Zhongqi Pharmaceutical)

rE-4

Phase 3 Clinical

Cspc Pharmaceutical Technology (Shijiazhuang) Co Ltd

Diabetes Mellitus, Type 2

Efpeglenatide

HM-11260C, LAPS-Exd4

Phase 3 Clinical

Hanmi Pharmaceutical Co Ltd

Diabetes Mellitus, Type 2, Obesity, Diabetes Mellitus